SKYE · Skye Bioscience, Inc. · Analyst Estimates
$1.02
-0.01 (-1.36%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Nov 13, 2026
Market Cap
$4.56M
Shares
4.42M
Volume · Nov 19
12.7K
Avg daily vol (62 sessions)
84.15K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Skye Bioscience, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-17 08:03 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-5.04
|
-5.04
|
-5.04
|
1
|
-5.04
|
-5.04
|
-5.04
|
-5.04
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
3
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-4.56
|
-4.56
|
-4.56
|
1
|
-7.40
|
-7.40
|
-7.40
|
-9.05
|
0
|
0
|
1
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
3
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.12
|
-1.12
|
-1.12
|
1
|
-1.12
|
-1.12
|
-1.12
|
-1.12
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
3
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.52
|
-1.52
|
-1.52
|
1
|
-1.88
|
-1.88
|
-1.88
|
-2.10
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
2
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1516551
CUSIP
83086J309
13F (30d)
32 filings
29 filers
Visit website
Investor relations